Profile data is unavailable for this security.
About the company
Disc Medicine, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps) including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
- Revenue in USD (TTM)0.00
- Net income in USD-80.60m
- Incorporated2020
- Employees74.00
- LocationDisc Medicine Inc321 Arsenal Street, Suite 101WATERTOWN 02472United StatesUSA
- Phone+1 (617) 674-9274
- Fax+1 (302) 655-5049
- Websitehttps://www.discmedicine.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prime Medicine Inc | 591.00k | -204.50m | 777.80m | 234.00 | -- | 3.19 | -- | 1,316.07 | -2.17 | -2.17 | 0.0062 | 2.03 | 0.0019 | -- | -- | 2,525.64 | -65.09 | -- | -70.51 | -- | -- | -- | -34,601.86 | -- | -- | -- | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
| ProKidney Corp | 0.00 | -35.30m | 806.31m | 163.00 | -- | -- | -- | -- | -0.567 | -0.567 | 0.00 | -17.79 | 0.00 | -- | -- | 0.00 | -30.32 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | 67.17 | -- | -- | -- |
| Evolus Inc | 219.70m | -60.00m | 809.55m | 279.00 | -- | 43.66 | -- | 3.68 | -1.05 | -1.05 | 3.82 | 0.2962 | 1.14 | 3.86 | 7.62 | 804,750.90 | -31.06 | -40.92 | -40.14 | -59.74 | 69.28 | 65.43 | -27.31 | -80.46 | 2.96 | -2.90 | 0.8674 | -- | 35.98 | -- | 17.10 | -- | 182.77 | -- |
| Praxis Precision Medicines Inc | 2.20m | -125.38m | 811.94m | 82.00 | -- | 2.74 | -- | 369.90 | -15.91 | -15.91 | 0.2394 | 17.32 | 0.0126 | -- | -- | 26,768.29 | -71.89 | -74.04 | -83.56 | -85.12 | -- | -- | -5,711.85 | -24,589.25 | -- | -- | 0.00 | -- | -- | -- | 42.40 | -- | -4.52 | -- |
| Disc Medicine Inc | 0.00 | -80.60m | 839.29m | 74.00 | -- | 2.48 | -- | -- | -3.37 | -3.37 | 0.00 | 13.69 | 0.00 | -- | -- | 0.00 | -26.96 | -- | -28.13 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.22 | -- | -- | -- |
| Zentalis Pharmaceuticals Inc | 40.56m | -218.90m | 843.64m | 168.00 | -- | 1.84 | -- | 20.80 | -3.36 | -3.36 | 0.5934 | 6.46 | 0.0775 | -- | 7.09 | 241,428.60 | -39.22 | -47.40 | -43.89 | -54.18 | -- | -- | -506.16 | -- | -- | -- | 0.00 | -- | -- | -- | -23.39 | -- | 20.76 | -- |
| Relay Therapeutics Inc | 35.33m | -329.12m | 850.87m | 309.00 | -- | 1.14 | -- | 24.09 | -2.64 | -2.64 | 0.2841 | 5.64 | 0.0376 | -- | -- | 109,371.50 | -35.03 | -28.55 | -37.16 | -29.54 | -- | -- | -931.64 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
| Tyra Biosciences Inc | 0.00 | -75.45m | 852.20m | 49.00 | -- | 2.18 | -- | -- | -1.68 | -1.68 | 0.00 | 7.43 | 0.00 | -- | -- | 0.00 | -22.87 | -- | -23.31 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.96 | -- | -- | -- |
| ARS Pharmaceuticals Inc | 10.00k | -49.70m | 860.43m | 24.00 | -- | 3.83 | -- | 86,042.98 | -0.5198 | -0.5198 | 0.0001 | 2.32 | 0.00004 | -- | -- | 416.67 | -19.93 | -20.37 | -20.48 | -21.32 | -- | -- | -496,960.00 | -17,491.75 | -- | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
| Perspective Therapeutics Inc | -304.00k | -48.91m | 881.04m | 116.00 | -- | 3.52 | -- | -- | -0.1622 | -0.197 | -0.0009 | 0.3917 | -0.0015 | -- | -- | -2,620.69 | -24.10 | -- | -25.46 | -- | -- | -- | -- | -- | -- | -- | 0.0074 | -- | -- | -- | -- | -- | -- | -- |
| Ocular Therapeutix Inc | 59.84m | -115.27m | 882.87m | 267.00 | -- | 2.16 | -- | 14.75 | -1.09 | -1.09 | 0.6335 | 2.64 | 0.1793 | 2.23 | 2.51 | 224,127.30 | -34.54 | -46.70 | -37.58 | -54.18 | 90.99 | 89.36 | -192.62 | -228.65 | 21.29 | -9.10 | 0.1401 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
| Humacyte Inc | 0.00 | -105.70m | 890.75m | 183.00 | -- | 34.06 | -- | -- | -1.01 | -1.01 | 0.00 | 0.2196 | 0.00 | -- | -- | 0.00 | -61.38 | -- | -68.92 | -- | -- | -- | -- | -- | -- | -61.50 | 0.4145 | -- | -100.00 | -- | -825.83 | -- | -- | -- |
| Immunome Inc | 12.68m | -232.03m | 895.93m | 55.00 | -- | 3.12 | -- | 70.64 | -5.49 | -5.49 | 0.4273 | 4.78 | 0.069 | -- | -- | 230,600.00 | -126.15 | -94.54 | -148.61 | -112.66 | -- | -- | -1,829.44 | -1,403.15 | -- | -- | 0.00 | -- | -- | -- | -184.68 | -- | 29.52 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Paradigm BioCapital Advisors LPas of 31 Mar 2024 | 2.39m | 9.68% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.09m | 4.42% |
| Perceptive Advisors LLCas of 31 Mar 2024 | 939.87k | 3.81% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 935.14k | 3.79% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 812.55k | 3.29% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 754.02k | 3.06% |
| Wellington Management Co. LLPas of 31 Mar 2024 | 670.48k | 2.72% |
| Adage Capital Management LPas of 31 Mar 2024 | 574.46k | 2.33% |
| Janus Henderson Investors US LLCas of 31 Mar 2024 | 516.43k | 2.09% |
| AllianceBernstein LPas of 31 Mar 2024 | 496.88k | 2.01% |
